Nevertheless, the high frequency of gastrointestinal symptoms may influence long-term adherence in routine clinical practice
Clinical programs using semaglutide have shown significant, sustainable weight loss when paired with medical support
The Endocrine Society's 2015 obesity pharmacotherapy guidelines recommend that "dose escalation be delayed for patients experiencing intolerable adverse events." This applies directly to GLP-1 agents and gives prescribers explicit guideline backing to slow the titration schedule when needed [12]
Whether you take semaglutide, tirzepatide, liraglutide, dulaglutide, or retatrutide, Shotsy helps you stay on schedule and reach your goals
TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: A double blind, placebocontrolled trial (Basel Thyroid Study)
Account for differences in bioavailability and titration schedules across injectables and oral forms